eriodictyol has been researched along with Colorectal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abalo, R; Capasso, R; Entrialgo-Cadierno, R; Fernández, J; Lombó, F; Silván, B; Uranga, JA; Villar, CJ | 1 |
| Gu, M; He, Y; Huang, H; Ji, L; Li, Y; Wu, M | 1 |
| Alper, M; Ardıl, B | 1 |
1 review(s) available for eriodictyol and Colorectal Neoplasms
| Article | Year |
|---|---|
Antiproliferative and palliative activity of flavonoids in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Flavanones; Flavonoids; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Luteolin; Palliative Care; Propiophenones | 2021 |
2 other study(ies) available for eriodictyol and Colorectal Neoplasms
| Article | Year |
|---|---|
Eriodictyol suppresses the malignant progression of colorectal cancer by downregulating tissue specific transplantation antigen P35B (TSTA3) expression to restrain fucosylation.
Topics: Carbohydrate Epimerases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Flavanones; Glycosylation; Guanosine Diphosphate Fucose; Humans; Ketone Oxidoreductases | 2022 |
Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Flavanones; Fluorouracil; Humans; Quassins | 2022 |